Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + valproic acid + valganciclovir for advanced EBV-positive nasopharyngeal carcinoma
NL-OMON34295Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, valproic acid and valganciclovir in nasopharyngeal carcinoma (NPC), sponsored by Netherlands Cancer Institute. Primary endpoint: Safety and tolerability. Started Oct 2011; status: active, not recruiting.
02
Drugs
gemcitabinevalproic acidvalganciclovir
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NL-OMON34295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34295.